This consultation closed on Wednesday, 17 March 2021.
The Therapeutic Goods Administration (TGA) is conducting a public consultation to provide industry and other interested stakeholders with an opportunity to comment on options for the TGA's proposed fees and charges for the 2021-22 financial year. Specifically, we are seeking feedback on the potential impact/s of the proposed options, prior to seeking approval from the Government for any changes.
The TGA within the Department of Health is responsible for the supply, import, export, manufacturing and advertising of therapeutic goods. The TGA recovers its costs from industry in accordance with Australian Government cost recovery arrangements. The Therapeutic Goods Act 1989 provides the legal authority for the TGA to charge for its regulatory activities. The Therapeutic Goods (Charges) Act 1989 provides the legal authority to levy annual charges on sponsors and manufacturers of medicines, biologicals and medical devices.
Timetable
Consultation paper is available through consultation hub from Thursday, 4 February 2021.
Interested parties should respond by close of business Wednesday, 17 March 2021.
Members of peak industry bodies that the TGA held bilateral meetings with (listed in the consultation paper) are encouraged to present their comments through the respective peak body so that the industry body can present a consolidated industry feedback to the TGA.
